Equities Analysts Set Expectations for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – HC Wainwright cut their Q1 2026 earnings estimates for shares of CervoMed in a report released on Tuesday, March 17th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.92) per share for the quarter, down from their prior estimate of ($0.86). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed’s Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.71) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.57) EPS and Q4 2027 earnings at ($0.62) EPS.

CRVO has been the topic of several other research reports. D. Boral Capital reiterated a “buy” rating and issued a $31.00 price objective on shares of CervoMed in a report on Monday. Cantor Fitzgerald started coverage on CervoMed in a report on Thursday, December 18th. They set an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a research report on Wednesday, January 21st. Zacks Research raised CervoMed from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Chardan Capital boosted their price objective on CervoMed from $15.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CervoMed currently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

CervoMed Stock Down 6.4%

NASDAQ CRVO opened at $4.24 on Thursday. The company has a 50-day simple moving average of $5.28 and a two-hundred day simple moving average of $7.21. CervoMed has a 12-month low of $3.58 and a 12-month high of $16.94. The firm has a market cap of $39.26 million, a price-to-earnings ratio of -1.42 and a beta of -0.77.

CervoMed (NASDAQ:CRVO) last released its earnings results on Friday, March 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.09). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.84 million. CervoMed had a negative net margin of 672.80% and a negative return on equity of 96.04%.

Institutional Trading of CervoMed

A number of institutional investors have recently modified their holdings of CRVO. Rhumbline Advisers grew its stake in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after purchasing an additional 1,526 shares during the last quarter. Marshall Wace LLP bought a new position in CervoMed during the 2nd quarter valued at approximately $76,000. XTX Topco Ltd purchased a new stake in CervoMed in the 4th quarter worth approximately $81,000. Jane Street Group LLC purchased a new stake in CervoMed in the 4th quarter worth approximately $88,000. Finally, GSA Capital Partners LLP bought a new stake in shares of CervoMed in the 3rd quarter worth approximately $91,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.

More CervoMed News

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: Positive Phase 2b RewinD‑LB results and regulatory alignment: CervoMed reported clinically meaningful Phase 2b data in dementia with Lewy bodies (DLB), obtained FDA and other regulator alignment on a planned global Phase 3 (≈300 patients) and selected the Phase 3 dose/formulation — a clear clinical catalyst if funding is secured. GlobeNewswire Release
• Positive Sentiment: HC Wainwright reiterates Buy and raised some EPS forecasts: HC Wainwright keeps a Buy rating and $25 target while updating quarterly and FY estimates (including an improved FY2026 loss estimate), reinforcing analyst support ahead of Phase‑3 planning. MarketBeat HC Wainwright Note
• Positive Sentiment: Additional analyst support: Chardan Capital raised its price target to $21 (Buy), which adds to upside narratives and widens the range of bullish targets. TickerReport / Benzinga
• Positive Sentiment: Insider buying and selective institutional buying: Company insiders have reported multiple purchases recently; some institutions added shares in Q4 2025 — a signal of insider confidence that may support sentiment. Quiver Quant Summary
• Neutral Sentiment: Other buy ratings: D. Boral Capital and Cantor Fitzgerald also have positive stances, contributing to a consensus skewed to Buy but with widely dispersed targets (median target cited ~$25). American Banking News
• Negative Sentiment: Cash runway and widening losses: Q4/2025 results show cash fell to ~$20.9M (≈ six months runway at current plan) and net loss widened to ≈$27M — funding needs for Phase 3 are material and could mean dilution or financing risk. GlobeNewswire Release
• Negative Sentiment: Mixed analyst moves — some cuts: Roth MKM cut its price target to $11 (from $19) despite a Buy rating, highlighting divergence among analysts on valuation and raising near‑term downside risk if funding or trial execution concerns grow. Benzinga

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.